Weidenauer, Ana
Bauer, Martin
Sauerzopf, Ulrich
Bartova, Lucie
Nics, Lukas
Pfaff, Sarah
Philippe, Cecile
Berroterán-Infante, Neydher http://orcid.org/0000-0002-9247-6457
Pichler, Verena
Meyer, Bernhard M.
Rabl, Ulrich
Sezen, Patrick
Cumming, Paul
Stimpfl, Thomas
Sitte, Harald H. http://orcid.org/0000-0002-1339-7444
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Mossaheb, Nilufar
Zimprich, Alexander
Rusjan, Pablo
Dorffner, Georg
Mitterhauser, Markus
Hacker, Marcus
Pezawas, Lukas http://orcid.org/0000-0002-1329-6352
Kasper, Siegfried
Wadsak, Wolfgang http://orcid.org/0000-0003-4479-8053
Praschak-Rieder, Nicole
Willeit, Matthäus
Article History
Received: 2 September 2019
Revised: 1 October 2019
Accepted: 1 November 2019
First Online: 8 January 2020
Conflict of interest
: Without relevance to this work, Matthäus Willeit declares to having received speaker honoraria and consulting fees from Janssen-Cilag Pharma GmbH, Austria. Without relevance to this work, Wolfgang Wadsak declares to having received speaker honoraria from GE Healthcare, research grants from Ipsen Pharma, Eckert-Ziegler AG, Scintomics and ITG. WW is a part time eployee of CBmed Ltd (Center for Biomarker Research in Medicine, Graz, Austria). Without relevance to this work Georg Dorffner is employee and shareholder of The Siesta Group GmbH, a clinical trial service provider in the area of electrophysiological measurements such as EEG. Harald Sitte received grants/research support, consulting fees and/or honoraria from AbbVie, Aesca, Amgen, Astellas, AstraZeneca, Astropharma, Chiesi, Gebro, IMH, IIR, Janssen-Cilag Lundbeck, MSD, Mundipharma, Pfizer, Ratiopharm, Roche, Sandoz, Serumwerk Bernburg, Shire, Vertex and is a member of advisory boards of Amgen, Chieri and Sanofi-Aventis. Marcus Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. Rupert Lanzenberger received travel grants and/or conference speaker honoraria from Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, Orphan Pharmaceuticals AG, Janssen-Cilag Pharma GmbH, and Roche Austria GmbH. Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Ana Weidenauer, Martin Bauer, Ulrich Sauerzopf, Lucie Bartova, Lukas Nics, Sarah Pfaff, Cecile Phelippe, Neydher Berroterán-Infante, Verena Pichler, Bernhard Meyer, Ulrich Rabl, Patrick Sezen, Paul Cumming, Thomas Stimpfl, Nilufar Mossaheb, Alexander Zimprich, Pablo Rusjan, Markus Mitterhauser, Lukas Pezawas, and Nicole Praschak-Rieder have no conflict of interest to declare.